Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-monitored adjuvant therapy study in high-risk HR-positive/HER2-negative early breast cancer
ISRCTN50261938Phase 2Suspended
- Sponsor
- Medica Scientia Innovation Research, S.L. (MEDSIR)
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of giredestrant, abemaciclib and inavolisib in breast cancer (4 arms), sponsored by Medica Scientia Innovation Research, S.L. (MEDSIR). Primary endpoint: ctDNA response at 3 months. Started Jan 2024; status: suspended.
02
Drugs
giredestrantabemaciclibinavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN50261938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50261938.